Recently a new identified genetic variant in the 3′-untranslated region of the prothrombin gene (G20210A allele) associated with increased plasma prothrombin levels has been linked to an increased risk of venous thromboembolism (VTE). To determine the importance of this G20210A allele as a causative risk factor for VTE in the general population, we analysed the data of an epidemiologic investigation on thrombophilia in young people, the Oporto Thrombophilia Study (PORtromb). Forty cases (mean age: 27 yr old) with a first episode of VTE under 40 yr old, and 100 healthy subjects, were evaluated. Heterozygosity for the G20210A allele was present in 12.5% of VTE cases and in 5% of controls, indicating a possible marginal increase of VTE risk in carriers of the allele (odds ratio: 2.71: 95% Cl 0.74–9.95).
DahlbackB., CarlssonM. and SvenssonP., Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulation response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Science USA, 1993, 90, 1004–1008.
4.
SvenssonP. J. and DahlbackB., Resistance to activated protein C as a basis for venous thrombosis. New England Journal of Medicine, 1994, 330, 517–522.
5.
BertinaR. M., KoelemanB. P. C., KosterT., Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, 369, 64–67.
6.
Van der MeerF. J. M., KosterT., VandenbrouckeJ. P., The Leiden Thrombophilia Study (LETS). Thrombosis and Hacmostasis, 1997, 78 (1), 631–635.
7.
PoortR. S., RosendaalF. R., ReitsmaP. H., A common genetic variation in the 3′-untranslated region of the protrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 1996, 88, 3698–3703.
8.
LindmarkerP., SchulmanS., Sten-LinderM., The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A alele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thrombosis and Haemostasis, 1999, 81, 684–689.
9.
TosettoA., MissiagliaE., FrezzatoM., The VITA Project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thrombosis and Haemostasis, 1999, 82, 1395–1398.
10.
MakrisM., PrestonF. E., BeauchampN. J., Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thrombosis and Haemostasis, 1997, 78, 1426–1429.
11.
RodeghieroF. and TosettoA., The epidemiology of inherited thrombophilia: the VITA Project. Thrombosis and Haemostasis, 1997, 78 (1), 636–640.
12.
SeligsohnU. and ZivelinA., Thrombophilia as a multigenic disorder. Thrombosis and Haemostasis, 1997, 78 (1), 297–301.
13.
RosendaalF. R., DoggcnC. J. M., ZivelinA., Geographic distribution of the 20210 G to A prothrombin variant. Thrombosis and Haemostasis, 1998, 79, 706–708.
14.
HillarpA., ZollerB., SvenssonP. J., The 2021 OA allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thrombosis and Haemostasis, 1997, 78, 990–992.
15.
RosendaalF. R., VosH. L., PoortS., Prothrombin 20210A variant and age at thrombosis. Thrombosis and Haemostasis, 1998, 79, 444.
16.
HowardT., MarusaM., BoiszaJ., The prothrombin gene 3′-untranslated region mutation is frequently associated with Factor V Leiden in thrombophilic patients and shows ethnic specific variation in allele frequency. Blood, 1998, 91 (Abstr), 1092.
17.
TosettoA., MissiagliaE., MartinelliI., Additional genetic risk factors for venous thromboembolism in carriers of FV Leiden. British Journal of Haematology, 1998, 103, 871–876.
18.
FerraresiP., MarchettiG., LegnaniC., The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in arterial disease. Arteriosclerosis Thrombosis and Vascular Biology, 1997, 17, 2418–2422.
19.
MartinelliI., SacchiE., LandiG., High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New England Journal of Medicine, 1998, 338, 1793–1797.
